Fig. 3: A subset of EGFR is confined within tetraspanin nanodomains and exhibits preferential EGF binding.
From: Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
ARPE-19 cells were treated with siRNA to silence CD81, or non-targeting siRNA (control), as indicated. A–I Results of SPT analysis. The cells were subjected to SPT using either Fab-Cy3B to label total EGFR in the absence or presence of unlabelled EGF, or labelled using EGF-Cy3B to label only ligand-bound EGFR. Shown in A–C are the mean ± SE of the fraction of EGFR tracks in each mobility category (immobile, confined, mobile) under each condition. In each of the panels A, B, we replot the same data to show only the immobile and confined fractions. Also shown are mean ± SE of diffusion coefficient (D–F) or the confinement radius (G–I). EGF-Cy3B (ligand-bound) data is from 4 independent experiments, and Fab-Cy3B (total EGFR) data is from 5 independent experiments. Each experiment involved detection and tracking of >500 EGFR objects. *p < 0.05. Statistical analysis and p-values are indicated in Supplementary Table 1. Source data are provided as a Source Data file.
